Incyte and Iconix Collaborate on Chemogenomic Product | GenomeWeb

NEW YORK, May 30 – Incyte Genomics and Iconix Pharmaceuticals announced on Wednesday a collaboration to develop and commercialize the next-generation of Iconix’s ChemExpress chemogenomic platform.

Incyte will exclusively market and sell ChemExpress, according to the companies. Iconix will integrate Incyte’s LifeExpress Lead databases into ChemExpress under an exclusive license from Incyte, the companies announced. Under the terms of the agreement, Incyte will make an equity investment in Iconix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.